<DOC>
	<DOC>NCT02793505</DOC>
	<brief_summary>This study aims to better characterize the risk linked to metformin use during pregnancy, using a prospective multicentric cohort design enabling a large sample size, in evaluating the rate of birth defects after first trimester exposure, as well as several other pregnancy related outcomes.</brief_summary>
	<brief_title>Safety of Metformin in Pregnancy</brief_title>
	<detailed_description />
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Exposed group: exposed to metformin (Anatomical Therapeutic Chemical A10BA02) any time during pregnancy (i. e. any time from conception to week 42 after last menstrual period (LMP)). Reference group: at no time during pregnancy were exposed to metformin, insulin or any other hypoglycaemic agent. exposed to any of the following known major teratogen or major fetotoxicant: acitretin, isotretinoin, mycophenolate, thalidomide, valproic acid, angiotensinII receptor blockers (only when used in 2nd or 3rd trimester), ACE inhibitors (only when used in 2nd or 3rd trimester), or (b) following treatment indications coded: malignancies (MedDRA code: malignant or unspecified tumors (SMQ 20000091), ICD10: C00D09)) or malignancy related conditions (MedDRA: SMQ 20000092), ICD10: C00D09). lost to followup</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>metformin</keyword>
	<keyword>pregnancy outcomes</keyword>
	<keyword>birth defects</keyword>
	<keyword>spontaneous abortion</keyword>
	<keyword>pharmacoepidemiology</keyword>
</DOC>